Top-Rated StocksTop-RatedNASDAQ:IMVT Immunovant (IMVT) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free IMVT Stock Alerts $32.31 -0.21 (-0.65%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$31.55▼$32.9550-Day Range$30.27▼$40.5452-Week Range$14.05▼$45.58Volume1.26 million shsAverage Volume1.27 million shsMarket Capitalization$4.69 billionP/E RatioN/ADividend YieldN/APrice Target$47.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immunovant alerts: Email Address Immunovant MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside48.6% Upside$48.00 Price TargetShort InterestBearish15.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 9 Articles This WeekInsider TradingSelling Shares$659,896 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.70) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 starsMedical Sector515th out of 938 stocksBiological Products, Except Diagnostic Industry86th out of 148 stocks 4.5 Analyst's Opinion Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.00, Immunovant has a forecasted upside of 48.6% from its current price of $32.31.Amount of Analyst CoverageImmunovant has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.30% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Immunovant has recently increased by 7.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMVT. Previous Next 3.2 News and Social Media Coverage News SentimentImmunovant has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Immunovant this week, compared to 4 articles on an average week.Search InterestOnly 12 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows17 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is an increase of 89% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $659,896.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Immunovant is held by insiders.Percentage Held by Institutions47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($1.70) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -17.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -17.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 11.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Immunovant Stock (NASDAQ:IMVT)Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Read More IMVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMVT Stock News HeadlinesMarch 26, 2024 | americanbankingnews.comTruist Financial Reaffirms "Buy" Rating for Immunovant (NASDAQ:IMVT)March 25, 2024 | investorplace.comWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichMarch 29, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 22, 2024 | markets.businessinsider.comBuy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab TrialsMarch 19, 2024 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Given Average Recommendation of "Buy" by AnalystsMarch 12, 2024 | finanznachrichten.deImmunovant Inc.: Immunovant Awarded U.S. Patent for IMVT-1402March 12, 2024 | globenewswire.comImmunovant Awarded U.S. Patent for IMVT-1402March 11, 2024 | finance.yahoo.comIMVT Jul 2024 30.000 callMarch 29, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 11, 2024 | finance.yahoo.comIMVT Mar 2024 40.000 callMarch 10, 2024 | finance.yahoo.comIMVT Mar 2024 32.000 callMarch 10, 2024 | finance.yahoo.comIMVT Apr 2024 45.000 putMarch 10, 2024 | finance.yahoo.comIMVT Jan 2025 12.500 putMarch 10, 2024 | finance.yahoo.comIMVT Mar 2024 29.000 putMarch 9, 2024 | finance.yahoo.comIMVT Mar 2024 37.500 putMarch 9, 2024 | finance.yahoo.comIMVT Mar 2024 37.000 callMarch 6, 2024 | finance.yahoo.comIMVT Mar 2024 32.000 putMarch 5, 2024 | finance.yahoo.comIMVT Mar 2024 33.000 putMarch 1, 2024 | finance.yahoo.comIMVT Mar 2024 36.000 callFebruary 26, 2024 | investorplace.com3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024February 24, 2024 | finance.yahoo.comImmunovant Inc CFO Eva Barnett Sells 2,930 SharesFebruary 23, 2024 | benzinga.comImmunovant Stock (NASDAQ:IMVT), Short Interest ReportFebruary 20, 2024 | msn.comJP Morgan Initiates Coverage of Immunovant (IMVT) with Overweight RecommendationFebruary 15, 2024 | markets.businessinsider.comBuy Rating Affirmed on Immunovant’s Promising Pipeline and Strategic Clinical AdvancementsFebruary 14, 2024 | finance.yahoo.comImmunovant Inc (IMVT) Reports Fiscal Q3 Results: Expands Clinical Programs Amid Rising R&D CostsFebruary 13, 2024 | markets.businessinsider.comBuy Rating Justified: Immunovant’s Strategic Clinical Advancements and Lead Drug Candidate PromiseFebruary 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Immunovant’s Expansion and IMVT-1402’s Market PotentialSee More Headlines Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/12/2024Today3/28/2024Fiscal Year End3/31/2024Next Earnings (Estimated)5/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMVT CUSIPN/A CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Target$48.00 High Stock Price Target$57.00 Low Stock Price Target$32.00 Potential Upside/Downside+48.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-210,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.97% Return on Assets-52.47% Debt Debt-to-Equity RatioN/A Current Ratio22.14 Quick Ratio22.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.78 per share Price / Book11.62Miscellaneous Outstanding Shares145,290,000Free Float138,319,000Market Cap$4.69 billion OptionableOptionable Beta0.67 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Frank M. Torti M.B.A. (Age 45)M.D., Executive Chairperson of the Board Comp: $92.5kDr. Peter Salzmann M.B.A. (Age 55)M.D., CEO & Director Comp: $1.02MMs. Eva Renee Barnett M.B.A. (Age 44)Chief Financial Officer Comp: $871.07kDr. William L. Macias M.D. (Age 66)Ph.D., Chief Medical Officer Comp: $719.88kDr. Jay S. Stout Ph.D. (Age 61)Chief Technology Officer Dr. Chau Cheng M.B.A.Ph.D., Vice President of Investor RelationsMr. Mark S. Levine (Age 51)Chief Legal Officer & Corporate Secretary Ms. Lauren Schrier M.B.A.Vice President of MarketingMs. Christine BlodgettVice President of Human ResourcesDr. Julia G. Butchko Ph.D. (Age 53)Chief Development Officer Comp: $531kMore ExecutivesKey CompetitorsKrystal BiotechNASDAQ:KRYSRevolution MedicinesNASDAQ:RVMDHalozyme TherapeuticsNASDAQ:HALOIovance BiotherapeuticsNASDAQ:IOVAApogee TherapeuticsNASDAQ:APGEView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 405,348 shares on 3/11/2024Ownership: 4.011%Wellington Management Group LLPBought 126,412 shares on 3/5/2024Ownership: 0.203%Goldman Sachs Group Inc.Sold 52,309 shares on 3/1/2024Ownership: 0.315%Perceptive Advisors LLCSold 1,486,609 shares on 2/26/2024Ownership: 1.602%Eva Renee BarnettSold 2,930 sharesTotal: $105,919.50 ($36.15/share)View All Insider TransactionsView All Institutional Transactions IMVT Stock Analysis - Frequently Asked Questions Should I buy or sell Immunovant stock right now? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares. View IMVT analyst ratings or view top-rated stocks. What is Immunovant's stock price target for 2024? 17 Wall Street analysts have issued 1-year target prices for Immunovant's stock. Their IMVT share price targets range from $32.00 to $57.00. On average, they anticipate the company's share price to reach $48.00 in the next year. This suggests a possible upside of 48.6% from the stock's current price. View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts. How have IMVT shares performed in 2024? Immunovant's stock was trading at $42.13 on January 1st, 2024. Since then, IMVT shares have decreased by 23.3% and is now trading at $32.31. View the best growth stocks for 2024 here. Are investors shorting Immunovant? Immunovant saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 9,350,000 shares, an increase of 7.7% from the February 29th total of 8,680,000 shares. Based on an average trading volume of 1,320,000 shares, the short-interest ratio is presently 7.1 days. Currently, 15.3% of the company's stock are sold short. View Immunovant's Short Interest. When is Immunovant's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our IMVT earnings forecast. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) issued its quarterly earnings results on Monday, February, 12th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. What ETFs hold Immunovant's stock? ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC).IQ Chaikin U.S. Small Cap ETF (CSML). What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ). Who are Immunovant's major shareholders? Immunovant's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.03%), Vanguard Group Inc. (4.01%), Point72 Asset Management L.P. (1.84%), Perceptive Advisors LLC (1.60%), Price T Rowe Associates Inc. MD (1.11%) and Price T Rowe Associates Inc. MD (1.10%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMVT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.